Record Display for the EPA National Library Catalog
RECORD NUMBER: 13 OF 51
|OLS Field Name||OLS Field Data|
|Main Title||Biomarkers for Psychiatric Disorders [electronic resource] /|
|Subjects||Medicine. ; Neurosciences. ; Psychiatry. ; Proteomics.|
Due to license restrictions, this resource is available to EPA employees and authorized contractors only
Blood and Brain Gene Expression in Major Psychiatric Disorders: A Search for Biomarkers -- Biomarkers in Schizophrenia -- Proteomic Strategies for Biomarker Discovery: From Differential Expression to Isoforms to Pathways -- Schizophrenia Biomarkers: A Means to Advance Disease Understanding, Diagnosis and Treatment -- RNA Biomarkers in Schizophrenia -- Metabolomics: A Global Biochemical Approach to the Discovery of Biomarkers for Psychiatric Disorders -- Animal Models for Schizophrenia: A Brief Overview -- Synaptoproteomics of Existing and new Animal Models of Depression -- Animal Models for Anxiety Disorders -- Animal Models of Affective Behaviors and Drug Addiction -- Neuroimaging Biomarkers in Schizophrenia -- Sleep EEG Provides Biomarkers in Depression -- Strategies to Identify Biomarkers for Depression -- Pharmacogenetics of Antidepressant Response -- Perspectives for an Integrated Biomarker Approach to Drug Discovery and Development -- Hunting for Peripheral Biomarkers to Support Drug Development in Psychiatry -- Biomarkers for the Development of Antidepressant and Anxiolytic Drugs -- DNA Biomarkers for Pharmacogenomics and Personalized Medicine -- Biological Modeling in the Discovery and Validation of Cognitive Dysfunctions Biomarkers. Biological markers, as physiological indicators of disease, hold immense promise for diagnostics and clinical drug trials. While for other complex disorders like diabetes and heart disease a limited number of markers are at hand, there are currently no biomarkers available for psychiatric disorders. Here diagnostic tools are restricted to the evaluation of behavioral and clinical phenotypes, a severe limitation for any scientific study. As in any other disease area a major goal is therefore the identification of markers that can categorize subsets of patients in a consistent manner. This will allow a more precise definition of psychiatric disorders and in turn facilitate investigations of the pathophysiology and enhance the ability for patient treatment. Biomarkers for Psychiatric Disorders provides discovery strategies from scientists in academia and pharma and biotech industries. By addressing the various potential uses of psychiatric biomarkers, this edited volume will interest psychiatrists, neuroscientists, and biomedical scientists working in molecular medicine, disease diagnostics, and drug development. Christoph W. Turck is head of the Proteomics and Biomarkers branch at the Max Planck Institute of Psychiatry and holds faculty appointments in the Department of Biochemistry at Ludwig Maximilians University Munich and the International Max Planck Research School for Molecular and Cellular Life Sciences.